BioNTech (NASDAQ:BNTX) Sees Strong Trading Volume - Should You Buy?

Shares of BioNTech SE (NASDAQ:BNTX - Get Free Report) saw strong trading volume on Tuesday . 254,365 shares changed hands during trading, a decline of 46% from the previous session's volume of 469,307 shares.The stock last traded at $127.06 and had previously closed at $120.21.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. UBS Group increased their price target on shares of BioNTech from $97.00 to $131.00 and gave the stock a "neutral" rating in a research report on Wednesday, September 18th. The Goldman Sachs Group raised BioNTech from a "neutral" rating to a "buy" rating and raised their target price for the company from $90.00 to $137.00 in a report on Friday, November 8th. Evercore ISI raised BioNTech from an "in-line" rating to an "outperform" rating and boosted their price target for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. HC Wainwright reaffirmed a "buy" rating and issued a $150.00 price objective on shares of BioNTech in a research note on Monday, November 18th. Finally, Morgan Stanley raised BioNTech from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $93.00 to $145.00 in a research note on Tuesday, September 24th. Three investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, BioNTech has a consensus rating of "Moderate Buy" and an average price target of $140.76.

BioNTech Trading Up 5.5 %

The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm has a fifty day simple moving average of $113.72 and a 200-day simple moving average of $102.79. The firm has a market cap of $30.42 billion, a P/E ratio of -60.42 and a beta of 0.18.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts' consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech's quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.73 EPS. On average, equities research analysts expect that BioNTech SE will post -3.72 earnings per share for the current year.

Institutional Investors Weigh In On BioNTech

Several large investors have recently modified their holdings of BNTX. FMR LLC grew its stake in shares of BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company's stock worth $748,243,000 after acquiring an additional 5,598,190 shares during the period. Fred Alger Management LLC purchased a new stake in BioNTech during the third quarter valued at about $59,485,000. Point72 Asset Management L.P. boosted its position in BioNTech by 283.5% during the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company's stock worth $37,103,000 after purchasing an additional 341,311 shares during the period. Braidwell LP purchased a new position in shares of BioNTech in the third quarter worth about $29,425,000. Finally, New York State Common Retirement Fund raised its position in shares of BioNTech by 457.9% in the third quarter. New York State Common Retirement Fund now owns 218,067 shares of the company's stock valued at $25,900,000 after purchasing an additional 178,981 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.